Assessment of Exercise Intensity in Cardiac Rehabilitation Programmes for Patients With Chronic Heart Failure
NCT ID: NCT01545102
Last Updated: 2012-03-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
21 participants
OBSERVATIONAL
2012-04-30
2013-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The critical factor in terms of eliciting a sufficient training effect while minimising risk is the intensity of the exercise performed. It is now widely accepted that the traditional methods of using fixed percentages of maximal heart rate or oxygen uptake to set exercise intensity include serious errors. The European Society of Cardiology recommends that cardiopulmonary exercise testing should be used to provide an objective evaluation of the metabolic demand of exercise. This allows physiologically meaningful reference points to be established for aerobic exercise prescription and is the solution to defining safe and effective training intensities. The next step is to determine whether this information can be transferred to a practical cardiac rehabilitation environment to set and monitor exercise intensity
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Identifying Markers of Exercise Training in Heart Failure
NCT05696652
A Novel Home-based Physical Activity Intervention for Stable Chronic Heart Failure Patients
NCT03677271
High-intensity Interval Versus Combined Exercise Training in CHF
NCT02387411
Effectiveness of a Cardiac Rehabilitation Program in Elderly Patients With Heart Failure.
NCT05393362
Effect of Personalized Follow-up in Adapted Physical Activities in Subjects With Chronic Heart Failure.
NCT06222762
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Study Aim Primary objective to describe the exercise intensity, defined by oxygen uptake (VO2) in terms of the individual physiological thresholds, in CHF patients undergoing CR according to current guidelines Primary end point: VO2 Secondary objectives Secondary objectives of this study are:-
1. To measure resting and exercising energy expenditure in order to a) establish the value of 1 MET (resting metabolic rate) for patients with CHF, and b) to establish the MET value (defined as multiples of resting metabolic rate) for exercises performed in CR sessions
2. To measure affective responses (feeling very bad - feeling very good; levels of energy - tiredness and tension - calmness) to exercise during CR sessions
3. To measure weekly physical activity level in CHF patients undergoing Phase III and IV CR.
For the secondary analysis the following secondary end points and parameters will be established
1. MET values, defined as multiples of resting oxygen uptake or resting metabolic rate (1 MET), for different CR exercises
2. Ratings of affective response on the Feelings Scale (FS) and ratings of perceived activation on the Felt Arousal Scale (FAS).
3. Average daily activity over 7 day period in terms of steps per day and periods spent sitting, standing and walking
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* New York Heart Association (NYHA) class I-III
* clinically stable for at least 4 weeks on optimised medication dosage according to current guidelines
Exclusion Criteria
* Untreated lifethreatening cardiac arrhythmias
* Acute heart failure (during initial period of haemodynamic instability)
* Uncontrolled hypertension
* Advanced atrioventricular block
* Acute myocarditis or pericarditis
* Symptomatic aortic stenosis
* Severe hypertrophic obstructive cardiomyopathy
* Acute systemic illness Intracardiac thrombus
* Progressive worsening of exercise tolerance of dyspnoea at rest over previous 35 days
* Significant ischaemia during low intensity exercise (\< 2 METS, \< 50W)
* Uncontrolled diabetes
* Recent embolism
* Thrombophlebitis
* New onset atrial fibrillation/flutter
* \> 1.8 kg increase in body mass over previous 13 days
* Concurrent, continuous or intermittent dobutamine therapy
* Decrease in systolic blood pressure with exercise
* NYHA Functional Class IV
* Complex ventricular arrhythmia at rest or appearing with exertion
* Supine resting heart rate \> 100 beats/min
* Patient is participating in a conflicting study, is unable to perform exercise testing
* Patient lacks the capacity to consent or cannot comply with study requirements
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Guy Lloyd
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Guy Lloyd
Consultant Cardiologist
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Guy W Lloyd, MD
Role: PRINCIPAL_INVESTIGATOR
Eastbourne General Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Eastbourne General Hospital
Eastbourne, East Sussex, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TN11-26
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.